Anzeige
Mehr »
Samstag, 16.08.2025 - Börsentäglich über 12.000 News
Neue Bohrergebnisse, Sichtgold und eine 7-fache Bewertungslücke, die zu groß ist, um sie zu ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q8LD | ISIN: BMG210A71016 | Ticker-Symbol: MX6A
Tradegate
13.08.25 | 16:58
0,895 Euro
-1,65 % -0,015
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
GRAND PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
GRAND PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8750,95015.08.
0,8750,94015.08.

Aktuelle News zur GRAND PHARMACEUTICAL GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.08.GRAND PHARMA (00512): DATE OF BOARD MEETING1
28.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP2
22.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE ...1
17.07.GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT1
17.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES ...1
07.07.SIR-Spheres® Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms330Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms...
► Artikel lesen
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln
07.07.Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma227Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN...
► Artikel lesen
07.07.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: A NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ...2
04.06.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE OPHTHALMIC DRUG CBT-001 COMPLETES THE ENROLLMENT OF ALL PATIENTS IN THE INTERNATIONAL ...3
12.05.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE III STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX COMPLETES PATIENT ENROLLMENT ...2
07.05.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN INTERNATIONAL MULTICENTER PHASE III ...-
07.05.Grand Pharmaceutical Group Limited: The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China377The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease...
► Artikel lesen
06.05.GRAND PHARMA (00512): CLARIFICATION ON CHINESE VERSION OF VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE ...-
06.05.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 SUCCESSFULLY REACHED ...-
25.04.GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT1
22.04.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S FIRST GENERIC FLUTICASONE PROPIONATE NASAL SPRAY IN CHINA APPROVED FOR COMMERCIALIZATION2
21.04.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE CLINICAL STUDY IN CHINA OF THE GLOBAL INNOVATIVE RDC GPN02006 ACHIEVED A MILESTONE BREAKTHROUGH1
14.04.Dividendenbekanntmachungen (14.04.2025)3.930 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  CLIQ DIGITAL AG  DE000A35JS40 - 0,04 EUR  COMET HOLDING AG  CH0360826991  1,5 CHF  1,6197 EUR  EMMI AG  CH0012829898  16,5 CHF  17,8174...
► Artikel lesen
10.04.GRAND PHARMA (00512): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 10 APRIL 20251
02.04.GRAND PHARMA (00512): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024-
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1